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Abstract The interaction of fatty acid substrate (palmitate) and 
inhibitor (metyrapone: 2-methyl-l,2-di-3-pyridyl-l-propanone) 
with cytochrome P-450 BM3 was analysed by UV-visible and 
circular dichroism spectroscopy, and by surface-enhanced 
resonance Raman scattering (SERRS). While visible spectros- 
copy provides information on the relative affinities of these 
compounds, SERRS provides additional novel data indicating 
palmitate-induced structural changes in the haem environment. 
SERRS also demonstrates that binding of both palmitate and the 
large nitrogenous ligand metyrapone occurs simultaneously to 
P-450 BM3 - highlighting the usefulness of this technique in 
probing haemoprotein active sites. 
Key words." Cytochrome P450 BM3; SERRS spectroscopy; 
Substrate interaction; Heine environment; CD 
1. Introduction 
Cytochrome P-450 BM3 (P-450 102) from Bacillus megate- 
rium is an unusual member of the P-450 monooxygenase 
superfamily of haemoprotein enzymes [1,2]. It is soluble 
(like all bacterial P-450s), but differs from other bacterial 
P-450s in two major respects. Firstly, while all other charac- 
terised bacterial P-450s are reduced by electrons from NADH 
via two other enzymes (a flavoprotein dehydrogenase and an 
iron sulphur ferredoxin), P-450 BM3 receives electrons from 
NADPH via a single protein (an FAD-  and FMN-containing 
NADPH cytochrome P-450 reductase similar to the mem- 
branous enzyme used by mammalian membrane-bound hepat- 
ic P-450 systems) [3]. Secondly, the BM3 P-450 (N-terminal) is 
fused to the reductase (C-terminal) in a single polypeptide [4]. 
This fusion protein arrangement is unlike other well charac- 
terised P-450s, but is similar to nitric oxide synthase [5]. The 
haem domain of P-450 BM3 shares greater primary structure 
homology with mammalian P-450 fatty acid hydroxylases 
than with any other bacterial enzyme and utilises a eukary- 
otic-like reductase system. Thus, P-450 BM3 currently rep- 
resents the most appropriate model structure for eukaryotic 
microsomal P-450 systems. 
The structure of the haem domain of P-450 BM3 has been 
solved [6]. It exhibits typical P-450 properties - possessing a
hexacoordinated low-spin ferric haem, ligated on the proximal 
face by a cysteine (Cys400) and on the distal face by a weakly 
bound water molecule. The haem is positioned at the base of a 
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solvent exposed channel between two c~-helices (helices I and 
L). Access to the haem distal face can only occur along this 
long hydrophobic hannel. Differential electron density map 
calculations using arachidonate confirmed this channel as the 
substrate binding site [6]. 
The ability to purify fully active intact P-450 BM3 and its 
haem-containing domain opens the way for detailed analysis 
of their active sites. In this paper, we have utilised visible 
absorption and CD spectroscopy to analyse the interaction 
of fatty acid substrates and the P-450 inhibitor metyrapone 
with the haem domain of P-450 BM3. The vibrational tech- 
nique of SERRS has also been used. This sensitive technique 
combines the molecular specificity of resonance Raman with 
an enhancement in scattering efficiency gained by coupling of 
the oscillating electric field of incident and scattered light with 
surface plasmons (waves of electrons) on roughened metal 
(e.g. gold, silver or copper) surfaces. Enhancement factors 
as large as l0 s over normal Raman scattering have been ob- 
served from haem chromophores adsorbed on silver colloids 
or electrodes [7,8]. 
2. Materials and methods 
2.1. E. coli strains, plasmid and bacteriophage vectors 
E. coli strain XL-1 Blue (supE44, hsdR17, recA1, gyrA46, thi, relA1, 
lac , F' [proAB +, lacI q, lacZAM15, Tnl0(tetr)]) [9] was used for plas- 
mid propagation and the overexpression f the gene encoding cyto- 
chrome P-450 BM3 (cypl02) and the PCR-generated sub-genes encod- 
ing its constituent haem 'domains'. Construction of plasmids used for 
expression of P-450 BM3 and its constituent domains in E. eoli. has 
been described previously [10]. Briefly, pBM23 consists of a 5 kb 
segment of B. megaterium chromosomal DNA (containing the 
CYPI02 gene) cloned as an XbaI-EcoRI restriction fragment into 
vector pUCll9 [11] and expression is from the Bacillus promoter. 
Plasmid pBM20 was used for the expression of the haem-containing 
domain of P-450 BM3 (residues 1472) and consists of an approx. 1.5 
kb PCR fragment of CYPI02 cut with EcoRI and BamHI (to generate 
cohesive nds as with pBM27) and cloned into pUC 118 [12] under the 
lac promoter. Other bacterial strains and vectors used in these studies 
have been described previously [10]. 
2.2. Molecular biology techniques 
DNA manipulations, bacterial transformations and other molecular 
techniques were performed using standard methods [9]. 
2.3. Expression and purification of intact cytochrome P-450 BM3 and 
its constituent haem domain 
E. coli transformants carrying plasmids encoding wild-type P-450 
BM3 and its constituent haem domain were grown overnight to high 
cell density in Terrific Broth plus antibiotic (ampicillin) [12]. IPTG 
inducer (final concentration 100 ~tg/ml) was added to facilitate xpres- 
sion from plasmids pBM20 (encoding the haem-containing domain). 
Intact P-450 BM3 was expressed from plasmid pBM23 under the 
control of its own promoter and without induction, as previously 
described [10]. 
Approx. 30 g of wet cell pellets were the starting points for poly- 
peptide purification. Following cell rupture using a French press (950 
lb/inch2), polypeptides were purified to homogeneity by successive 
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steps of ammonium sulphate precipitation (2~60% fraction retained), 
ion-exchange chromatography on DEAE-Sephacel and either affinity 
chromatography on 2',5'-ADP-Sepharose (intact P-450 BM3) or by 
affinity for Bio-Gel HTP (DNA grade) hydroxyapatite (haem domain) 
as previously described [10]. Purification of the polypeptides by gel 
filtration using Sephacryl S-300 HR was used as a final purification 
step, when required. 
2.4. Spectroscopy, protein and enzyme assays 
Protein concentrations were determined using the method of Brad- 
ford [13] and by the BCA technique [14] with BSA as standard. Cy- 
tochrome P-450 concentrations were estimated by the method of 
Omura and Sato [15] using e=91 mM -1 cm -1 at 450 nm for the 
reduced plus CO adduct. NADPH-dependent fatty acid hydroxylation 
was measured at 30°C in 20 mM MOPS buffer (pH 7.4) containing 
100 mM KC1, using e = 6.2 mM -1 cm -1 at 340 nm. The assay system 
contained 0.25 mM sodium palmitate or sodium laurate and 0.2 mM 
NADPH. CD spectra were recorded on a Jasco J-600 spectropolar- 
imeter. Far UV CD spectra were analysed for secondary structure by 
the CONTIN procedure [16]. 
For SERRS spectroscopy, colloidal silver was prepared according 
to a method modified from that originally reported by Lee and Meisel 
[17]. The procedure has been extensively described in a recent pub- 
lication [18]. The approximately monodispersed suspension formed 
was stable for 6-8 weeks. Fresh samples of enzymes (P-450 BM3 
holoenzyme or BM3 haem domain (10-40 gM)) were prepared in 
100 gl of 100 mM sodium phosphate buffer (pH 7.5). 10 20 gl of 
the protein solution was then added to 290-280 I, tl of ice-cold 100 mM 
sodium phosphate buffer (pH 5.8) and the solution left on ice for 15 
rain. This solution was added to 2 ml of cooled Ag colloid and in- 
cubated on ice. 35 lal of 1% w/v L-ascorbic acid (Sigma, > 99%) was 
added, initiating aggregation of the colloid. SERR spectra were re- 
corded at 2-60C, 30 min after initial aggregation. 
For substrate-bound SERRS studies, 12 gl of a 75 mM methanolic 
solution of palmitate was added to P-450 BM3 haem domain in 300 gl 
of 100 mM sodium phosphate buffer (see above). For inhibitor-bound 
studies, 15 gl of 5 mM metyrapone was added to both substrate-free 
and palmitate-bound protein. In both cases, SERRS determinations 
were carried out as described above. 
Spectra-Physics argon ion (2020/2045) continuous wave lasers pro- 
vided 50 mW of 514.5 nm excitation. Data acquisition and analysis 
equipment have been described elsewhere [18]. A scanning rate of 1 
cm 1 s 1 was employed for spectral acquisition. 
2.5. Mater&Is 
Molecular biology reagents were purchased from Boehringer or 
United States Biochemicals. DEAE-Sephacel was purchased from 
Pharmacia-LKB. Silver nitrate (> 99%) was obtained from Aldrich. 
All other reagents and enzymes were obtained from Sigma. 
3. Results 
3.1. Visible spectroscopic analysis of  fatty acid interaction with 
P-450 BM3 
The haem domain of cytochrome P-450 BM3 exhibits visi- 
ble absorbance properties typical of  other P-450s, with an 
Table 1 
Selected vibrational bands of the P-450 BM3 haem domain in the 
presence and absence of palmitate 
Vibrational mode Frequency (cm 1) 
Substrate-free P-450 Palmitate-bound P-450 
v4 1372 1372 
v29 1400 
v3 1493 1493 
v2 1572 1570 
vc c 1628 1628 
P-450 BM3 haem domain was at 1.6× 10 -7 M. Palmitate was added 
to a final concentration f 3 × 10 -3 M. Experiments were performed 
as stated in Section 2. 
350.0 400.0 450.0 460.0 
Navelength (nm.) 
Fig. 1. Absorption difference spectra caused by titration of metyra- 
pone into palmitate-bound P-450 BM3 haem domain. To cyto- 
chrome P-450 BM3 haem domain (0.8 gM) was added saturating 
(5 gM) palmitate in 20 mM MOPS (pH 7.4) containing 100 mM 
KC1 at 30°C. Thereafter titration with metyrapone (from 100 mM 
aqueous tock solution) was performed resulting in shift of the 
absorbance peak from 390 nm back to 419 nm. Spectra shown are 
at metyrapone concentrations of: (a) 0.6 mM, (b) 1.1 mM, (c) 2.04 
mM, (d) 2.94 mM, (e) 5.06 mM and (f) 8.76 mM. 
intense Soret band located at 419 nm and the smaller c~ and 
bands at approx. 570 and 535 nm, respectively. The haem 
iron is essentially all low-spin until addition of substrate. On 
binding of palmitate and other substrates, a type I absorbance 
shift occurs - with the Soret band moving to 390 nm. The 
amount of absorbance change induced by the addition of 
known quantities of fatty acids allows calculation of the asso- 
ciation constants (Ks) for various substrates. Such analysis 
indicates Ks values of approx. 90 gM for lauric acid, 2 laM 
for palmitic acid and 6 ~tM for arachidonic acid with the 
haem domain. 
Addit ion of the P-450 inhibitor metyrapone to a solution of 
substrate-free P-450 BM3 haem domain does not result in a 
significant change in the visible absorption spectrum. How- 
ever, titration of metyrapone this into a solution of fatty 
acid-bound enzyme induces high-spin to low-spin conversion 
in the haem iron, indicating the affinity of the inhibitor for the 
P-450 BM3 haem domain active site (Fig. 1). On the basis of 
inhibition of P-450 BM3 palmitate and laurate monooxygen- 
ase activities, the Ki for metyrapone was estimated at 4.1 + 0.7 
mM. Further, on the basis of the extent of high-spin to low- 
spin conversion of palmitate-bound P-450 BM3 haem domain 
caused by titration of metyrapone, the Ks for metyrapone was 
estimated at 9.8 + 1.3 mM. 
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3.2. Circular dichroism studies on P-450 BM3 haem domain 
CD spectra of cytochrome P-450 BM3 haem domain were 
recorded in the presence and absence of substrates. The sub- 
strate-free nzymes exhibit far UV CD patterns typical of 
proteins with a high c~-helical content. Application of the 
CONTIN  procedure [16] indicates that the protein consist of 
34% c~-helix. The addition of excess substrate (palmitate or 
arachidonate at 250 gM) does not perturb the far UV CD 
spectrum (approx. 190-260 nm) to any significant extent - 
indicating that addition of substrates does not result in major 
alterations in secondary structure, either through the binding 
of fatty acids in the active site or via interaction at the surface 
of the protein. It should also be noted that there is negligible 
change in the near UV CD signal between 260 and 320 nm on 
addition of fatty acids. This region of the spectrum provides 
information on the tertiary structure of proteins, and the lack 
of change indicates that no gross tertiary structural change 
occurs on fatty acid binding. In the visible CD range, the 
haem domain exhibits negative ellipticity over the majority 
of the spectrum from 300 500 nm. The spectrum of the 
haem domain has a large absorbance trough centred at 412 
nm a wavelength slightly different from that of the peak 
seen in the visible absorption spectrum (419 nm) (Fig. 2). 
Changes are clearly seen in the visible CD region after sub- 
strate addition. On addition of excess palmitic or arachidonic 
acid, there is a shift of the major absorption trough to lower 
wavelength (approx. 405 nm) (Fig. 2). Again, this wavelength 
is somewhat different from that at which the substrate-bound 
forms have absorbance maxima in the electronic absorption 
spectrum (390 nm). Despite its clear inhibitory action, the 
addition of metyrapone does not cause obvious changes in 
the far UV or visible CD spectra. 
3.3. SERR spectroscopy on cytochrome P-450 BM3 haem 
domain 
SERRS of substrate-free P-450 BM3 haem domain was 
obtained with excitation at 514.5 nm (Table 1). The vibra- 
tional nomenclature is adopted from Abe et al. [19]. The 
SERRS indicated a predominantly high-spin species for the 
protein adsorbed on the silver colloid. The position of spin- 
state sensitive bands v3 and v2 at 1493 and 1572 cm 1 con- 
firms a contraction of the core ring indicative of a pentacoor- 
dinate porphyrin species [20]. Upon the addition of palmitate, 
further conversion to the high-spin state was observed. Addi- 
tionally, a relative enhancement of the band at 1401 cm 1 
occurred. This mode has been attributed to the v29 band of 
Table 2 
Vibrational bands for P-450 BM3 haem domain in the presence of 
palmitate and excess metyrapone (2.5 × 10 -4 M) 
Vibrational nomenclature ~ Raman frequency (cm 1) 
v~ b ~ 1679 
vl0 1637; low-spin 
v2 1580; low-spin 
v3 1502; low-spin 
v29 1400 
v4 1372 
Vb ~ 1053 
v~. u 1032 
Final P-450 and palmitate concentrations were 1.6 × 10 -7 and 3 × 10 --:~ 
M, respectively. Experiments were performed as stated in Section 2. 
~From [19]. 
bVibrational mode from metyrapone. 
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Fig. 2. Effect of palmitate addition on the visible region circular di- 
chroism spectra of P-450 BM3 haem domain. The near UV and 
visible region CD spectrum of P-450 BM3 haem domain (1 laM) 
was recorded in 50 mM Tris (pH 7.5) at 25°C. Thereafter, palmitate 
was added to a final concentration of 200 gM. The substrate-free 
oxidised protein (Ox.) exhibits negative ellipticity over the entire 
Soret region of the CD spectrum (approx. 330 nm~,60 nm). A shift 
in the position of the visible CD Soret band to lower wavelength 
occurs on addition of palmitate (Subs.) (CD minimum moving from 
412 to 405 nm), reflecting the different haem environment in the 
substrate-bound haem domain. 
the porphyrin macrocycle (Table 1). The v29 vibration results 
from coordinate movements of peripheral methylene substitu- 
ents, with iron-pyrollic nitrogen contributions. It is sensitive 
to structural alterations in the environment of the haem vinyl 
groups - and palmitate binding clearly causes such a structur- 
al perturbation. 
Addition of an excess of the P-450 inhibitor metyrapone to 
P-450 BM3 haem domain causes a large conversion to the 
low-spin state, indicative of the ligation of the nitrogenous 
ligand, as demonstrated by the appearance of the v2, v3 
and v l0  spin-state marker bands at 1580, 1502 and 1637 
cm -1, respectively (Table 2). Vibrational bands assigned to 
metyrapone itself are positioned at 1679 cm -1 (v~), 1053 
cm 1 (vb) and 1032 cm -1 (vc) (Fig. 3). Addition of metyra- 
pone to palmitate-bound haem domain also results in the 
formation of a low-spin species. The presence of the enhanced 
v29 band at 1400 cm -1 (a fatty acid-induced vibration) indi- 
cates that the substrate is still retained within the pocket. 
4. Discussion 
Substrate-free P-450 BM3 haem domain adsorbed onto col- 
loid yields SERR signals which are dominated by a high-spin 
species. SERRS signals are specific to the haem chromophore. 
Upon addition of metyrapone to palmitate-bound haem do- 
main, conversion to the low-spin haem species occurs. The 
inference is that metyrapone has penetrated into the palmi- 
tare-containing pocket, combining with the iron and causing 
formation of the hexacoordinated low-spin ferric haem. The 
low-spin conversion supports metyrapone binding to haem 
iron [21,22] although no low frequency band has been as- 
signed to metyrapone ligated to the haem. This is in agree- 
ment with the UV-visible and CD data, where the natural 
form of the protein observed in solution is low-spin and no 
significant changes are observed in the signals on addition of 
metyrapone. 
The presence of palmitate within the pocket of this low-spin 
haem is demonstrated by the appearance of the mode assigned 
to v29 at 1400 cm -1. The SERRS intensity of the v29 mode 
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Fig. 3. SERRS spectra of metyrapone-bound and metyrapone/palmi- 
tare-bound P-450 BM3 haem domain. The concentration of protein 
used was 1.6× 10 -7 M. (a) Spectrum of the metyrapone-bound spe- 
cies (metyrapone concentration=3.3x 10 -5 M). (b) Spectrum result- 
ing from addition of both metyrapone (3.3 x 10 -5 M) and palmitate 
(5 × 10 -4 M). Band assignment is identical to that in Table 2. Sam- 
ples were prepared as described in Section 2. 
relative to v4 increases upon the addition of palmitate to the 
P-450 BM3 haem domain. It is probable that the hydrophobic 
substrate positions itself against he rigid ~-sheet of the bind- 
ing pocket, held in place by non-ionic interactions which pre- 
vent haem/palmitate interaction. This binding would alter 
amino acid secondary and tertiary structural alignments. A1- 
losteric transmission of this effect to the ferriprotoporphyrin 
IX ring, via amino acids in close proximity to the haem, may 
result in an enhancement of the sensitive v29 mode. 
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Visible absorption and visible CD studies how changes in 
the Soret region associated with the binding of fatty acids. 
However, far UV CD is not sufficiently sensitive to detect 
any haem pocket deformations associated with their binding. 
By contrast, SERRS indicates that binding of palmitate (and 
other fatty acids) to the haem domain causes enhancement of 
modes such as v29 (which is sensitive to the nature of the 
interaction of the haem ring with the immediate protein en- 
vironment) but does not indicate direct interaction with the 
iron (no changes in v3 or v4). This finding is in agreement 
with the NMR data of Modi et al. [23] and suggests an allo- 
steric mechanism for v29 intensity increase. It would appear 
that, despite its distance, the binding of fatty acid is 'sensed' 
by the haem group of the enzyme, most likely through small 
deformations in the amino acid environment of the fatty acid 
being transmitted through to the haem. On the basis of po- 
tentiometric studies performed with P-450cam, it is likely that 
fatty acid binding of induces an increase in the midpoint po- 
tential of the P-450 BM3 haem iron, such that it rises above 
that of reduced FMN in the reductase domain and can accept 
electrons from this flavin. The low-spin to high-spin conver- 
sion caused by fatty acid binding is thought to involve the 
removal of a water molecule from the coordination sphere of 
the haem iron. 
Addition of metyrapone to cytochrome P-450 BM3 inhibits 
fatty acid hydroxylation. However, the binding of metyrapone 
does not cause obvious changes in the visible spectra of P-450 
BM3. SERRS clearly demonstrates band changes associated 
with the binding of metyrapone alone (changes in v3 and vl0) 
and palmitate alone (change in v29) to the active site of P-450 
BM3 haem domain. Moreover, the fact that both sets of 
changes are observed in the presence of fatty acid and metyra- 
pone indicates that the active site of P-450 BM3 is sufficiently 
large to accommodate both compounds at once. 
The data presented emonstrate he usefulness of the spec- 
troscopic technique of SERR in the analysis of molecular 
association with P-450 BM3. Fluorescence from the protein 
is quenched on the surface and only small quantities of en- 
zyme (nM) are required. By contrast, resonance Raman spec- 
troscopy demands micromolar amounts of enzyme. In addi- 
tion, the technique has provided information on the binding 
of compounds which is not forthcoming from other spectro- 
scopic techniques. Neither the binding of metyrapone nor the 
fatty acid-induced haem conformational change is detectable 
by UV-visible absorption spectroscopy or CD in any region of 
the spectrum. SERR spectroscopy identifies both phenomena, 
and provides evidence that simultaneous binding of fatty acid 
and metyrapone can occur in the P-450 BM3 active site. 
Modi et al. [23], used NMR to show that lauric acid was 
bound at nearly 0.8 nm from iron in oxidised P-450 BM3, 
sufficiently far to permit the co-binding of pyridine. This si- 
tuation is different from P-450cam, where camphor/pyridine 
co-binding is not feasible. Only small igands (such as cyanide) 
can bind simultaneously with camphor [24]. In this manu- 
script, we have used SERR spectroscopy to demonstrate 
that co-binding of the larger inhibitor molecule metyrapone 
is also feasible in the presence of palmitate. Fatty acid sub- 
strates in P-450 BM3 are bound at too great a distance from 
the haem for monooxygenation to occur. It appears that re- 
duction of fatty acid-bound P-450 BM3 brings about a move- 
ment of substrate closer to the haem and facilitates oxygena- 
tion at the c0-1, (o-2 or o)-3 positions [25]. This process may 
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involve the movement of residue F87, a putative electron 
transfer pathway amino acid, which protrudes into the active 
site of P-450 BM3 above the haem iron [6]. We are currently 
addressing this problem with SERR and other spectroscopic 
analyses of P-450 BM3 mutants, including those at residue 
F87. 
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